ANG-3070 - Fibrokinase Inhibitor Program

ANG-3070 is an orally bioavailable small molecule fibrokinase inhibitor in advanced preclinical development for treatment of chronic kidney disease and polycystic kidney disease.

We discovered a class of novel kinase inhibitors that targets several cellular receptors involved in fibrosis that scars and damages organs including the kidney. Our most advanced candidate is ANG-3070, an orally bioavailable small molecule, which has shown efficacy in preclinical renal fibrosis models both alone and in combination with current standard-of-care therapy. ANG-3070 also has shown anti-fibrotic activity in fibrocystic kidney and liver disease as well as NASH with advanced fibrosis.



ANG 4201 - ROCK2 Inhibitor

The Rho kinase family members, consisting of Rho-associated kinase1 (ROCK1) and ROCK2, are serine–threonine kinases that are activated by Rho GTPases. We have confirmed the upregulation of ROCK2 in animals models of renal disease which is associated with increases in renal collagen, hydroxyproline and alpha-SMA, markers of renal fibrosis.

We are employing state of the art core-hopping method and structure-based drug design to develop orally bioavailable and highly selective ROCK2 versus ROCK1 inhibitors for the treatment of renal fibrosis. We have identified ANG 4201 as our lead candidate which is a selective for ROCK2 and has shown promising antifibrotic effects in preclinical animal models of kidney disease. We believe that our selective ROCK2 inhibitor will not only prove efficacious in mitigating fibrosis but will also carry a lower risk of side effects associated with chronic dosing.